Cigna's most recent trend suggests a bearish bias. One trading opportunity on Cigna is a Bear Call Spread using a strike $210.00 short call and a strike $215.00 long call offers a potential 40.85% return on risk over the next 21 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $210.00 by expiration. The full premium credit of $1.45 would be kept by the premium seller. The risk of $3.55 would be incurred if the stock rose above the $215.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Cigna is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Cigna is bearish.
The RSI indicator is at 43.73 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Cigna
Cigna (CI) Extends Medicare Advantage in North Carolina
Tue, 24 Nov 2020 23:01:11 +0000
Cigna (CI) is providing Medicare Advantage business in 63 new counties within the state of North Carolina.
Why Now May Be the Time to Buy Health Care Stocks
Tue, 24 Nov 2020 12:30:00 +0000
Stocks of health-care companies are cheap in historical terms, and the recent election results are a positive for those businesses.
Cigna Affordable Care Act Health Plans to Expand into 63 New Counties Across North Carolina for 2021
Mon, 23 Nov 2020 14:00:00 +0000
Cigna is expanding access to health coverage through the Affordable Care Act (ACA) marketplace in 63 counties across North Carolina for 2021. Cigna's plans on the individual exchange will include a number of features that increase access to quality health care – all while holding down out-of-pocket costs.
GoodRx downplays feared Amazon effect: Pharmacy ‘not particularly impactful to our business'
Fri, 20 Nov 2020 23:20:42 +0000
“I’m sure Amazon would love to ship your medications to you, but it’s really, really hard to do,” GoodRx's CEO explained to Yahoo Finance on Friday.
GoodRx CEO Shrugs Off $5 Billion Dive on Amazon Pharma Move
Fri, 20 Nov 2020 15:04:07 +0000
(Bloomberg) — Newly-listed GoodRx Holdings Inc. got caught in the crosshairs of Amazon.com Inc.’s latest plans to shake up the drug industry, triggering a wipeout of about $5 billion in market value in just two days. But its chief executive officer is shrugging it off.The Santa Monica, California-based company, mostly known for its prescription-drug pricing app, plunged to a record low of $33.51 on Wednesday in the wake of Amazon’s plans to sell medicines to its U.S. Prime members. GoodRx drew its first analyst downgrades after the news, with some saying Amazon’s foray could dampen the company’s growth.GoodRx Squarely in Amazon Crosshairs With Pharmacy Launch: ReactGoodRx shares have rebounded more than 15% in the last two trading sessions, though the stock has still shed more than 30% of its value from an Oct. 6 high. Wall Street analysts are split about its future returns, with seven buy-rated followers compared to six with hold equivalents and one sell. At least one analyst has upgraded the stock.Co-founder and chief executive officer Douglas Hirsch dismissed some of the gloom. The business of mail orders for medicines is challenging, he said, and even with the pandemic and regional lockdowns, the number of Americans getting their medicines through the mail has lingered at around just 5%.“Mail order is really hard. The road is littered with companies that tried to offer mail order,” Hirsch told Bloomberg News.A handful of analysts and industry experts were ambivalent about the move, suggesting Amazon was joining the drug distribution channel but won’t fundamentally change it.Amazon has so far only tapped Inside Rx, a unit of Cigna Corp.’s pharmacy benefit manager Express Scripts as a partner. Amazon’s discount card may also just be a way for it to adhere to regulations around publishing drug prices, according to analysts at RBC Capital Markets.Hirsch said GoodRx can survive the blow of increased competition because of the high barriers to entry for new players in the space. GoodRx’s relationships with most PBMs, as well Inside Rx, means it’s able to offer better pricing on medicines than most of Amazon’s cash discounts.“They are our partner, it’s not a winner take all scenario,” said Hirsch, who noted you can also use a GoodRx card on Amazon.Amazon representatives didn’t respond to emailed requests for comment.Buying OpportunityInvestor Eric Jackson, founder of EMJ Capital Ltd., agrees with Hirsch. He took a chance on this week’s rout and picked up shares of GoodRx for his hedge fund.“On day one, Amazon announces that the Death Star is coming in to kill the business and the stock collapses and people panic,” Jackson said. “Looking back, it turns out to be a great buying opportunity from those kind of blood-in-the-streets type moments and I think this will be the same for their GoodRx.”The tech-focused hedge fund manager pointed to similar competitive fears for Twilio Inc. and Roku Inc.Twilio has surged more than 1,000% since September 2017 when investors fled the stock on Amazon’s promise to offer similar texting features as the cloud computing company. Roku has advanced more than 260% after a double-threat from Apple and Amazon last year.“I’ve seen this movie before many times: Amazon is going to kill company X,” Jackson said. “It rarely works out.”(Updates share moves in third paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Also on Market Tamer…
Follow Us on Facebook